Inhibition of neuronal nicotinic receptors can be regulated by the presence of specific amino acids in the ␤ subunit second transmembrane domain (TM2) domain. We show that the incorporation of a mutant ␤4 subunit, which contains sequence from the muscle ␤ subunit at the TM2 6Ј and 10Ј positions of the neuronal ␤4 subunit, greatly reduces the sensitivity of receptors to the local anesthetic [2-(triethylamino)-N-(2,6-dimethylphenyl)acetamide] (QX-314). Although differing in potency, the inhibition of both wild-type ␣3␤4 receptors and ␣3␤4(6ЈF10ЈT) receptors by QX-314 is voltage-dependent and noncompetitive. Interestingly, the potency of the local anesthetic tetracaine for the inhibition of ␣3␤4 and ␣3␤4(6ЈF10ЈT) receptors seems unchanged when measured at Ϫ50 mV. However, whereas the onset of inhibition of wild-type ␣3␤4 receptors is voltage-dependent and noncompetitive, the onset of inhibition of ␣3␤4(6ЈF10ЈT) receptors by tetracaine is unaffected by membrane voltage, and at concentrations Յ30 M seems to be competitive with acetylcholine. This may be due to either direct effects of tetracaine at the acetylcholine binding site or preferential block of closed rather than open channels in the mutant receptors. Further analysis of receptors containing the 6Ј mutation alone suggests that although the 6Ј mutation is adequate to alter the voltage dependence of tetracaine inhibition, both point mutations are required to produce the apparent competitive effects.
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The members of the neuronal nicotinic gene family have unique patterns of expression in the nervous system and are related to the nicotinic receptor genes that code for subunits of the muscle-type acetylcholine receptor. In total, 12 different genes have been cloned so far that demonstrably code for neuronal nicotinic receptor subunit proteins, based on their ability to form functional receptors when expressed in Xenopus laevis oocytes. Functional combinations of mammalian neuronal-type receptor subunits identified so far contain an ␣2, ␣3, ␣4, ␣7, ␣8, ␣9, or ␣10 subunit, and those containing ␣2, ␣3, or ␣4 must also contain a ␤ subunit (␤2 or ␤4). Although functional neuronal-type receptors require only one or two different types of subunits, they are believed to have a pentameric configuration similar to that of muscle-type receptors (Cooper et al., 1991) . It has been proposed that all of the nicotinic subunits have a similar topology, with the relatively hydrophilic amino-terminal half constituting a major extracellular domain of the protein, followed by three hydrophobic transmembrane domains, a large intracellular loop, and then a fourth hydrophobic transmembrane span. The binding sites for agonist activation of the receptors are in the extracellular domain, and it is generally accepted that channel gating and ion conduction are associated with the second transmembrane domain (TM2).
As the focus of gating-associated conformational change, sequence in TM2 of the nAChR is critical not only for the direct binding of channel blocking agents but also for determining the accessibility/affinity of binding sites in other parts of the receptor that may be linked to TM2 by the conformational dynamics of gating and/or desensitization (Francis et al., 1998) . We have recently shown that for neuronal nicotinic ␤ subunit-containing receptors, there can be a reciprocal dependence for the sensitivity to noncompetitive inhibition by mecamylamine and the desensitization or autoinhibition by agonists (Webster et al., 1999) . Specifically, changes in the amino acid sequence of the ␤ subunit TM2 domain, which diminish sensitivity to mecamylamine, increase the inhibitory or desensitizing effects of agonists. Complementary changes in the amino acid sequence of the muscle ␤ subunit TM2 domain increase the sensitivity of that receptor to mecamylamine and other noncompetitive antagonists [e.g., BTMPS (Webster et al., 1999) ], establishing this ␤ subunit domain as a crucial factor for nicotinic receptor pharmacology.
In the present study, we extend our analysis of noncom-petitive antagonists to two local anesthetics, QX-314 and tetracaine. Our experiments use mutant forms of the receptor that have been characterized as differing in their sensitivity to the ganglionic blocker mecamylamine. Like mecamylamine, QX-314 and tetracaine are both believed to be voltage-dependent channel blockers of nAChR. However, QX-314 and tetracaine differ from one another in their state dependence for inhibition. Specifically, whereas QX-314 most effectively inhibits channels in the open state (Neher, 1983) , tetracaine binds to both the resting and open states of muscle-type receptors (Papke and Oswald, 1989) . We hypothesized that substitution of sequence from the muscle ␤ subunit at the 6Ј and 10Ј positions of the ␤4 TM2 domain would reduce the sensitivity of receptors containing the mutant subunits to the local anesthetics we examined. We found that the ␤4 TM2 6Ј and 10Ј mutations change the potency of QX-314 but have no apparent effect on the mechanism of inhibition. Interestingly, these same mutations had no significant effect on the potency of tetracaine inhibition at our standard holding potential. However, mutant receptors containing the 6Ј and 10Ј substitutions differ from wild-type receptors in the voltage dependence of tetracaine inhibition and, furthermore, show competition effects between ACh and tetracaine.
Materials and Methods
cDNA Clones. For our experiments, we used the rat cDNA clones for the neuronal receptors (Heinemann et al., 1986) . The sequences of the TM2 domains of the relevant subunits are shown below. Adopting the terminology proposed by Miller (1989) , the 20 residues in the proposed second transmembrane sequence are identified as 1Ј through 20Ј (Table 1) Construction of Site-Directed Mutants. Site-directed mutagenesis was conducted with QuikChange kits (Stratagene, La Jolla, CA). In brief, two complementary oligonucleotides were synthesized that contain the desired mutation flanked by 10 to 15 bases of unmodified nucleotide sequence. Using a thermal cycler, Pfu DNA polymerase extended the sequence around the whole vector, generating a plasmid with staggered nicks. Each cycle built only off the parent strands; therefore, there was no amplification of misincorporations. After 12 to 16 cycles, the product was treated with DpnI, which digested the methylated parent DNA into numerous small pieces. The product was then transformed into Escherichia coli cells, which repaired the nicks. Mutations were confirmed by DNA sequencing.
Preparation of RNA. After linearization and purification of cloned cDNAs, RNA transcripts were prepared in vitro using the appropriate mMessage mMachine kit from Ambion Inc. (Austin, TX).
Expression in X. laevis Oocytes. Mature (Ͼ9 cm) female X. laevis African toads (Nasco, Ft. Atkinson, WI) were used as a source of oocytes. Before surgery, frogs were anesthetized by placing the animal in a 1.5 g/l solution of 3-aminobenzoic acid ethyl ester (MS222) for 30 min. Oocytes were removed through an incision made in the abdomen.
To remove the follicular cell layer, harvested oocytes were treated with 1.25 mg/ml collagenase from Worthington Biochemicals (Freehold, NJ) for 2 h at room temperature in calcium-free Barth's solution (88 mM NaCl, 10 mM HEPES, pH 7.6, 0.33 mM MgSO 4 , and 0.1 mg/ml gentamicin sulfate). Subsequently, stage 5 oocytes were each isolated and injected with 50 nl (5-20 ng) of a mixture of the appropriate subunit cRNAs. Recordings were made 1 to 7 days after injection, depending on the cRNAs being tested.
Chemicals. QX-314, tetracaine, and all other chemicals for electrophysiology were obtained from Sigma Chemical Co. (St. Louis MO). Fresh acetylcholine stock solutions were made daily in Ringer's solution and diluted.
Electrophysiology. Oocyte recordings were made with a OC-725C oocyte amplifier (Warner Instruments, Hamden, CT) interfaced to either a Macintosh or Gateway personal computer. Data were acquired using LabVIEW software (National Instruments, Austin, TX) or pClamp8 (Axon Instruments, Union City, CA) and filtered at a rate of 6 Hz. Oocytes were placed in a Warner RC-8 recording chamber with a total volume of about 0.6 ml and perfused at room temperature with frog Ringer's solution (115 mM NaCl, 2.5 mM KCl, 10 mM HEPES, pH 7.3, and 1.8 mM CaCl 2 ) containing 1 M atropine to inhibit potential muscarinic responses. A Mariotte flask filled with Ringer's solution was used to maintain a constant hydrostatic pressure for drug deliveries and washes. Drugs were diluted in perfusion solution and loaded into a 2-ml loop at the terminus of the perfusion line. A bypass of the drugloading loop allowed bath solution to flow continuously while the drug loop was loaded, and then drug application was synchronized with data acquisition by using a two-way electronic valve. The rate of bath solution exchange and all drug applications was 6 ml/min. Current electrodes were filled with a solution containing 250 mM CsCl, 250 mM CsF, and 100 mM EGTA and had resistances of 0.5 to 2 M⍀. Voltage electrodes were filled with 3 M KCl and had resistances of 1 to 3 M⍀.
Experimental Protocols and Data Analysis. Current responses to drug application were studied under two-electrode voltage clamp at a holding potential of Ϫ50 mV unless otherwise noted. Holding currents immediately before agonist application were subtracted from measurements of the peak response to agonist. All drug applications were separated by a wash period of 5 min unless otherwise noted. At the start of recording, all oocytes received two initial control applications of 100 M ACh. Subsequent drug applications were normalized to the second ACh application to control for the level of channel expression in each oocyte. The second application of control ACh was used to minimize the effect of rundown that occasionally occurred after the initial ACh-evoked response. To measure residual inhibitory effects, the experimental coapplications of ACh and inhibitor were followed, after a 5-min washout, by another application of ACh alone. This subsequent control response was compared with the preapplication control ACh response. Means and S.E. were calculated from the normalized responses of at least four oocytes for each experimental concentration.
For concentration-response relations, data were plotted using Kaleidagraph 3.0.2 (Abelbeck Software, Reading, PA), and curves were generated from the Hill equation: Response ϭ (I max [agonist] nH ) / ( [agonist] nH ϩ (EC 50 ) nH ), where I max denotes the maximal response for a particular agonist/subunit combination, and n H represents the Hill coefficient. I max , n H , and the EC 50 were all unconstrained for the fitting procedures. Negative Hill slopes were applied for the calculation of IC 50 values.
For experiments assessing voltage dependence of inhibition, oocytes were voltage-clamped at the indicated holding potential for both control applications of ACh alone and test applications of experimental agonists and/or antagonists. After a 5-min wash period, cells were given another control ACh application at the indicated potential so that residual inhibition could be evaluated.
Results

TM2 Mutations Change the Potency of the Local Anesthetic QX-314 but Not the Mechanism of Inhibition.
As shown in Fig. 1 , the introduction of ␤1 subunit sequence into the 6Ј and 10Ј positions of the ␤4 TM2 domain reduces the QX-314 sensitivity of receptors formed by coexpression with ␣3. Specifically, as shown in Fig. 2A , ␣3␤4(6ЈF10ЈT) receptors are about 50-fold less sensitive to inhibition by QX-314 than are wild-type receptors (Table 2) . When the inhibition produced by QX-314 was measured over a range of transmembrane voltages, it seemed that the inhibition of both the mutant and wild-type receptors was voltage-dependent ( Fig. 2B) . Likewise, when the concentration-response functions for ACh were determined in the absence and presence of fixed QX-314 concentrations (1 M and 100 M for wild-type and mutant receptors, respectively) for both receptors, QX-314 inhibition seemed to be noncompetitive (Fig. 2, C and D) . However, whereas QX-314 coapplication reduced the ACh maximum responses of both the wild-type and mutant receptors, there was no significant effect on the ACh EC 50 of the wild-type receptors, but there was a shift in apparent ACh potency with the mutant receptors ( Table 3) . TM2 Mutations Do Not Change the Potency of the Local Anesthetic Tetracaine but Do Change the Apparent Mechanism of Inhibition. As shown in Fig. 3 , the introduction of the ␤1 sequence into the 6Ј and 10Ј positions of the ␤4 TM2 domain had relatively little effect on the responses of ␣3-containing receptors to the coapplication of tetracaine and ACh. However, after the application of tetracaine, there was a significant decrease in the control ACh responses of the ␤4(6ЈF10ЈT)-containing receptors. Interestingly, when a concentration-response analysis of tetracaine inhibition was conducted at our standard holding potential of Ϫ50 mV, there seemed to be no significant effect of the ␤4 (6ЈF10ЈT) mutations (Fig. 4A ). However, when the effect of tetracaine was examined across a range of voltages, it was clear that although the peak responses of wild-type ␣3␤4 receptors showed a significant voltage dependence, the inhibition of ␣3␤4(6ЈF10ЈT) receptors during the coapplication of tetracaine and ACh was unaffected by voltage ( Fig. 4B) . Although there was no significant difference in the inhibition of wild-type and mutant receptors by 10 M tetracaine when the cells were held at Ϫ50 mV, wild-type receptors were far more sensitive (p Ͻ 0.01) to 10 M tetracaine than were the mutants when the cell was held at Ϫ100 mV. We confirmed this difference in voltage dependence by conducting another concentration-response analysis with a holding potential of Ϫ100 mV. As shown in Fig. 5 , compared with the data obtained at Ϫ50 mV, the concentration-response function measured at the hyperpolarized potential shifted to the left for the wild-type receptors (see Table 2 ) but not for the ␣3␤4(6ЈF10ЈT) receptors.
We further investigated this apparent qualitative difference in tetracaine-induced inhibition by conducting ACh concentration-response analyses in the absence and presence of a fixed (10 M) concentration of tetracaine. As shown in Fig.  4C , the effect of tetracaine on wild-type receptors fit the predictions for noncompetitive inhibition. Surprisingly, however, the effect of tetracaine on the ACh responses of ␣3␤4(6ЈF10ЈT) receptors seems more consistent with a competitive mechanism of inhibition (Fig. 4D) . By increasing ACh concentration, the relative amount of inhibition by 10 M tetracaine was decreased. Although this would be consistent with an inhibitory effect of tetracaine mediated by competition with ACh at the activation site, this interpretation is complicated by the fact that ACh itself may be binding to multiple sites, including sites that intrinsically limit functional response (Webster et al., 1999) .
To determine whether the TM2 mutations change the relative affinity of tetracaine for the open and closed states of the receptor, we conducted preapplications of 30 M tetracaine immediately before the application of 100 M ACh. We accomplished this by inserting into our perfusion system a second drug application loop that could be filled indepen- Inhibition by Local Anesthetics dently from the ACh application loop. With this method, some mixing does occur between the tetracaine and ACh solutions in the bath; however, most of the tetracaine application is delivered to receptors before ACh-evoked activation. The inhibition of wild-type receptors produced by the preapplication of 30 M tetracaine was significantly less (p Ͻ 0.05) than that produced when tetracaine was coapplied with the ACh. The responses were 45 Ϯ 7% of the ACh controls with preapplication, compared with 20 Ϯ 5% with coapplication (for the coapplication data, see Fig. 4A ). In contrast, the mutant receptors showed nearly identical levels of peak current inhibition under these two conditions; responses were reduced to 30 Ϯ 2% of the ACh controls with preapplication, compared with 36 Ϯ 7% with coapplication. These results suggest that for the mutant receptors, inhibition by tetracaine may occur equally well with open and closed receptors.
To determine whether the apparent competitive effects of tetracaine on the mutant receptors were consistent over a wide range of tetracaine concentrations or whether, as previously suggested for muscle-type receptors (Papke and Oswald, 1989) , multiple forms of inhibition by tetracaine might exist, additional competition experiments were conducted using 100 M tetracaine in coapplication with ACh at varying concentrations. As shown in Fig. 5C , this increased concentration of tetracaine both decreased the maximum response and increased the EC 50 of the ACh concentrationresponse relationship (Table 3) . We evaluated the recovery of ␣3␤4(6ЈF10ЈT) receptor ACh control responses 5 min after the application of ACh alone or coapplied with either 10 or 100 M tetracaine (Fig. 5D ). Whereas coapplication of 10 M tetracaine had no significant effect on the recovery of ACh control responses, when 100 M tetracaine was coapplied with high concentrations of ACh (300 M-3 mM), there was a greater (p Ͻ 0.01) depression of subsequent ACh responses. Therefore, whereas the preapplication experiment suggests that lower concentrations of tetracaine may inhibit both open and closed ␣3␤4(6ЈF10ЈT) receptors, at this high concentration, tetracaine may have additional long-term effects based on a preferential interaction with open channels.
Analysis of Single and Double Mutations: QX-314. We have previously shown that mutations at the 6Ј and 10Ј positions ␤1 or ␤4 have additive effects for the reversal of mecamylamine sensitivity and the enhancement of agonistinduced inhibition (Webster et al., 1999) . Therefore, we sought to determine whether both mutations contributed to the decrease in QX-314 sensitivity in ␣3␤4(6ЈF10ЈT) receptors. As shown in Fig. 6A , the 10Ј mutation has a sensitivity to QX-314 that is intermediate to the wild-type and ␤4(6ЈF10ЈT)-containing receptors. When the inhibition measured during the coapplication of QX-314 and ACh is considered, the decrease in sensitivity of the 6Ј mutants seems to be nearly the same as that of the 6Ј/10Ј double mutant. However, the 6Ј single mutants are, in fact, more sensitive to QX-314 than the 6Ј/10Ј double mutants, as can be seen in an increase in the residual inhibition persisting after a 5-min wash (Fig. 6A, inset) . QX-314 inhibition is readily reversible Fig. 3 . At the standard holding potential of Ϫ50 mV, ␣3␤4(6ЈF10ЈT) mutant receptors seem at least as sensitive to inhibition by tetracaine as wild-type ␣3␤4 receptors. A, representative traces recorded from oocytes expressing wild-type ␣3␤4 receptors showing the initial control application of 100 M ACh (dark line), then a response to the coapplication of 100 M ACh and 100 M tetracaine (gray line). A final control application of 100 M ACh response is also shown (arrow) indicating the degree of recovery. Each of these three responses was separated by 5-min washes. B, representative traces recorded from cells expressing the double mutant ␣3␤4(6ЈF10ЈT) receptors using the same experimental protocol, indicating that these receptors are equally sensitive to blockade by tetracaine.
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in the wild-type receptors (Francis et al., 1998) ; thus, the appearance of prolonged inhibition in the 6Ј mutants was unexpected. It would seem that the 6Ј mutation may particularly affect the kinetics of QX-314, making the onset of inhibition slower (and therefore showing less inhibition during the coapplication response, compared with the wild type) but also slower to dissociate. Therefore, it would seem that both the 6Ј and 10Ј mutations are essential to determine the QX-314 sensitivity. Analysis of Single and Double Mutations: Tetracaine. In an analysis of inhibition during coapplication of ACh and tetracaine, it seemed that only the 6Ј mutation was required to remove the voltage sensitivity of inhibition by tetracaine during the coapplication response (Fig. 6B) . However, when residual inhibition of ␣3␤4(6ЈF) receptors was measured after a 5-min wash, there was a greater residual effect on cells held at Ϫ100 mV than on cells held at Ϫ50 mV (p Ͻ 0.05). Cells held at Ϫ50 mV recovered to 88 Ϯ 8% of the pretreatment control and cells held at Ϫ100 mV recovered to only 60 Ϯ 6% (Fig. 6B) . This was similar to the results obtained with the double mutant (Fig. 6B) .
In an attempt to determine whether the 6Ј mutation is also sufficient to produce the apparent change in mechanism observed during inhibition of the double mutants by tetracaine (see Fig. 4, C and D) , we conducted a competition experiment with a single concentration of ACh and tetracaine in cells expressing ␣3 and the ␤4(6ЈF) mutant. Specifically, 1 mM ACh was applied with or without 10 M tetracaine, to determine whether this relatively high concentration of ACh would be able to surmount the tetracaine inhibition of the coapplication response, as is the case with the double mutant (Fig. 4D) . We found that when 10 M was coapplied with 1 mM ACh to ␣3␤4(6ЈF) receptors, the normalized responses were only 51 Ϯ 6% (n ϭ 4) of the size of the normalized responses to 1 mM ACh alone. This result was similar to the results obtained with the coapplication responses of ␣3␤4 wild-type receptors (Fig. 4C) . Thus, although it seems that the 6Ј mutation is sufficient to alter the voltage dependence of the onset of tetracaine inhibition, the presence of this mutation alone is not adequate to produce the apparent change in mechanism of tetracaine inhibition that we observed.
Discussion
We chose to investigate the effects of channel mutations on the inhibition of neuronal-type nAChR by tetracaine and QX-314 because previous studies indicated that these local anesthetics differed in their mechanisms for the inhibition of muscle-type nAChR. Lidocaine and the related compounds QX-314 (lidocaine n-ethyl bromide) and QX-222 have been shown to preferentially block muscle-type nAChR from the extracellular side (Horn et al., 1980) , producing inhibition based on an affinity for a site within the open ion channel. Tetracaine, in contrast, has been shown to block muscle-type receptors in both open and closed states (Papke and Oswald, 1989) . In our experiments, we sought first to determine whether these compounds also differed in their mechanisms for the inhibition of wild-type ␣3␤4 receptors, as they do for muscle-type receptors. We then sought to determine whether mutations of the neuronal ␤ subunit TM2 domain to the sequence of the muscle ␤ subunit would make the inhibitory effects of these compounds on neuronal receptors more like their effects on muscle-type receptors.
It has been shown previously that both the 6Ј and 10Ј residues of the mouse muscle receptor subunits can influence receptor inhibition by lidocaine and the related quaternary compounds QX-314 and QX-222 (Charnet et al., 1990; Pascual and Karlin, 1998) . Charnet et al. (1990) proposed that the 6Ј residues provide a polar site within the channel that interacts with the charged amine of these local anesthetics, 
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whereas the 10Ј residues contribute to a hydrophobic binding site. However, in the profile of the muscle receptor, the residues of the ␤ subunit do not fit the model for the ideal QX-314 binding site. The muscle ␤ subunit has a hydrophobic phenylalanine at the 6Ј site and a relatively polar threonine at the 10Ј site. These residues would not be expected to contribute to the proposed polar and hydrophobic binding sites, and it was shown that appropriate polar and hydrophobic mutations at the 6Ј and 10Ј sites of the muscle ␤1 subunit, respectively, had the effect of increasing inhibition by QX-222 (Charnet et al., 1990) . In the present experiments, the 6ЈF and 10ЈT mutations would both serve to disrupt the QX-314 binding site predicted by the Charnet two-site model, placing hydrophobic residues at the proposed 6Ј polar site and more polar residues at the proposed hydrophobic site. Our results are therefore consistent with this two-site model of the QX-314 binding site, with the net effect on the potency of QX-314 being particularly strong, because in the neuronal receptor complexes, each mutation is presumably present in at least two subunits of the pentamer.
Although the effects of the (6ЈF10ЈT) mutations on inhibition by QX-314 are consistent with a simple decrease in the affinity of QX-314 for an open-channel-associated site, the effects of the (6ЈF10ЈT) mutations on inhibition by tetracaine are more complex. The degree of inhibition during a coapplication of ACh and tetracaine did not seem to differ in the mutant receptors compared with wild-type when measurements were made during the coapplication at the standard holding potential of Ϫ50 mV. However, the apparent potency of tetracaine was voltage-dependent in the wild-type receptors but not in the (6ЈF10ЈT) mutants. Interestingly, whereas there was no apparent voltage dependence of the inhibition measured during the coapplication of tetracaine and ACh, there was an effect of voltage on the reversibility of inhibition with the (6ЈF10ЈT) mutant receptors that was not detectable in the wild-type. Another qualitative difference in the effects of tetracaine on (6ЈF10ЈT) mutant receptors was the apparent state dependence for inhibition. In the mutant receptors, inhibition did not depend on the presence of agonist, so inhibition could be obtained if tetracaine was applied before Fig. 2 ). The main figure shows the effect measured during coapplication of 100 M ACh and varying concentrations of QX-314. From these data, it would seem that the 6Ј mutation was essentially as effective as the 6Ј10Ј double mutation at reducing the potency of QX-314. However, when subsequent ACh control responses were measured after a 5-min wash (shown on right), it was noted that the 6Ј mutant showed a residual inhibition that the 6Ј10Ј mutants did not. This observation suggests that the 6Ј mutation may be more effective at changing the kinetics of QX-314 inhibition than the actual potency because inhibition of wild-type receptors by QX-314 was fully reversible over the same time period (not shown). B, the effects of single point mutations on the voltage sensitivity of tetracaine-evoked inhibition. Oocytes were treated with 100 M ACh plus 10 M tetracaine at a holding potential of either Ϫ50 or Ϫ100 mV. After a 5-min wash at the test potential, control applications of ACh were measured and expressed relative to initial control responses obtained at the same potential. Although the data measured during the coapplication of ACh and tetracaine might suggest that the 6Ј mutation alone was sufficient to eliminate the voltage-dependence of tetracaine-evoked inhibition; in fact, inhibition of the 6Ј mutant was more persistent at Ϫ100 mV than at Ϫ50 mV (see text).
ACh. Finally, inhibition by 10 M tetracaine (a concentration close to the apparent IC 50 values) can be surmounted by increasing agonist concentration in the mutant receptors but not the wild-type receptors. That is, tetracaine shifted the ACh EC 50 of the mutant receptors but had no effect on the maximum response. However, when the IC 80 concentration of tetracaine was used, there was both a larger shift in the ACh EC 50 and a decrease in the maximum response (Table  3) .
These data seem to be consistent with multiple interpretations. One hypothesis would be that tetracaine binds to different sites in the wild-type and mutant receptors. Specifically, at least some of the inhibitory effects in the mutant receptor might arise from a direct interaction between tetracaine and ACh at the activation binding site. Alternatively, the binding site for tetracaine might be preferentially exposed or have a higher affinity in the open state of the wild-type receptor, whereas in the mutant receptor tetracaine may bind equally well to both open and closed receptors or even show a preference for binding to closed receptors. If that is the case, then it is possible that preferential binding to closed receptors might appear as a competitive interaction, because increasing agonist concentrations would take the channels away from the state for which the antagonist would have the highest affinity.
Whereas tetracaine does seem to bind primarily to a noncompetitive site in wild-type muscle receptors (Middleton et al., 1999) , at high concentrations, it can also compete with agonist (Ryan and Baenziger, 1999) . Tetracaine has even been reported to activate mouse muscle-type receptors of BC3H-1 cells (Papke and Oswald, 1989) , although tetracaineevoked channel openings are difficult to detect because of the concomitant channel-blocking activity. Additionally, singlechannel data indicated that whereas low concentrations of tetracaine produced inhibition by binding to a site that did not require the channel to be in an open state, higher concentrations of tetracaine seemed to promote increased blockade of open channels. Therefore, data from muscle-type receptors would be consistent with the existence of as many as three different, potentially inhibitory, binding sites for tetracaine. There is evidence for two channel-associated sites that differ in state dependence and might also differ in voltage dependence, based on the disposition of the sites in the membrane's electric field. In addition to producing effects at these channel-associated sites, tetracaine would also inhibit the responses of muscle-type receptors to strong agonists because of its activity as a weak partial agonist. Certainly, analogs of these sites may exist in the wild-type and mutant neuronal AChR used in this study. Mutation of the neuronal subunit to the muscle ␤ subunit sequence may alter the relative affinity of tetracaine for these corresponding sites in the neuronal ␤ subunit mutant.
Although it seems that in the wild-type neuronal receptors, tetracaine produces inhibition in a manner similar to that of QX-314, presumably through open-channel block, it may be that the (6ЈF10ЈT) mutations decrease the affinity of tetracaine for the open-channel site. However, because under standard recording conditions, the potency of tetracaine was relatively unaffected in the mutant receptors, it seems likely that if activity is lost at an open-channel site, the effects of tetracaine at alternative sites or for alternative activation states (i.e., closed channels) may be increased. Specifically, in the mutant receptors, tetracaine may be more able to block closed channels. If the binding site in the closed channel were not as deep in the membrane's electric field as the openchannel block site, it would account for the apparent decrease in voltage dependence. Alternatively, tetracaine may bind more effectively to the agonist binding site of mutant receptors. This would be consistent with the apparent competitive effects observed with ACh and 10 M tetracaine. The EC 50 for ACh was increased 3-fold in the presence of 10 M tetracaine. The apparent EC 50 for ACh was further increased when ACh was applied in the presence of 100 M tetracaine, also consistent with competitive inhibition. However, the fact that inhibition by 100 M tetracaine could not be fully surmounted by increasing ACh concentration would argue against inhibition arising solely from competitive interactions at the ACh binding site.
Despite having information about the molecular shapes and hydrophobicity of the drugs, without a better knowledge of the structure of the channel in both the open and closed states, we can only speculate how the mutations in TM2 account for our results. QX-314 is "ellipsoid" with a less polar but bulkier quaternary ammonium group than tetracaine's. Tetracaine is more "rod-like", with a methylammonium group that is smaller and more polar in this part of the molecule. However, it remains difficult to model the drugs in the channel, because we cannot be sure whether the ammonium groups of both drugs bind closest to the cytosol in the wild-type receptor, as has been suggested for the QX-314 orientation in the muscle-type receptor (Charnet et al., 1990) . Both tetracaine and QX-314 seem to be binding differently in the mutant compared with the wild-type channels. In the case of QX-314, there seems to be a loss of affinity but not a change in binding site or state dependence. In the case of tetracaine, there may be relative changes in binding to multiple sites or differences in the state dependence of binding to a single site. However, we cannot know whether the point effects of the mutations or more global effects on channel structure cause the effects we observe. Because the tetracaine ammonium group is less polar than that of QX-314, it may be the case that the interaction with the phenylalanine would be stronger with QX-314. We might then speculate that QX-314 would remain more stable with the amine deep in the channel in both the wild-type and mutant but that tetracaine might preferentially change its orientation in the mutant channel, with the amine group more toward the extracellular surface. This could account for the reduced voltage-dependence we observed, if the binding site for the charged group of tetracaine is altered so that it is less deep in the channel.
In conclusion, our data indicate that QX-314 and tetracaine inhibit wild-type ␣3␤4 receptors through similar mechanisms, such that for both drugs the inhibition is voltagedependent and noncompetitive, consistent with open-channel blockade. This is in agreement with data for QX-314 inhibition of wild-type muscle nAChR. The TM2 mutations do not seem to alter the mechanism for QX-314 inhibition but do change the inhibition produced by tetracaine. Similar to what has been reported for muscle-type AChR, tetracaine inhibits ␣3␤4(6ЈF) receptors in a manner consistent with the block of both open and closed channels and perhaps involving competitive as well as noncompetitive interactions. The findings of the present study are consistent with our previous Inhibition by Local Anesthetics report that ␤ subunit TM2 sequence affects the state-dependent inhibition of muscle-type and neuronal nAChR by the voltage-independent noncompetitive inhibitor BTMPS (Francis et al., 1998) . Our results therefore support the hypothesis that sequence in the ␤ subunit TM2 may regulate channelblocking mechanisms, not only via direct effects at channelassociated sites but also via conformational changes occurring with channel gating and extending beyond the open channel domain.
